Jin LM, Shen H, Che XY, Jin Y, Yuan CM, Zhang NH. Anti-bacterial mechanism of baicalin-tobramycin combination on carbapenem-resistant Pseudomonas aeruginosa. World J Clin Cases 2023; 11(17): 4026-4034 [PMID: 37388786 DOI: 10.12998/wjcc.v11.i17.4026]
Corresponding Author of This Article
Neng-Hua Zhang, Doctor, Associate Chief Physician, Laboratory Department, Jiaxing Hospital of Traditional Chinese Medicine, No. 1501 Zhongshan East Road, Jiaxing 314001, Zhejiang Province, China. znhshzyxwx@163.com
Research Domain of This Article
Methodology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 16, 2023; 11(17): 4026-4034 Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.4026
Anti-bacterial mechanism of baicalin-tobramycin combination on carbapenem-resistant Pseudomonas aeruginosa
Li-Min Jin, Hui Shen, Xing-Ying Che, Ye Jin, Chun-Mei Yuan, Neng-Hua Zhang
Li-Min Jin, Hui Shen, Xing-Ying Che, Ye Jin, Chun-Mei Yuan, Neng-Hua Zhang, Laboratory Department, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314001, Zhejiang Province, China
Author contributions: Jin LM is mainly responsible for experimental design and writing articles; Shen H is mainly responsible for collecting data and samples; Chen XY conducted experimental operations and conducted statistical analysis of articles; Jin Y and Yuan CM are responsible for specimen selection and experimental operations; Zhang NH is responsible for experimental guidance and important revisions to the article, and all authors read and approved the final version.
Supported byJiaxing Science and Technology Planning Project, No. 2019AY32006 and No. 2020AY30004.
Institutional review board statement: The study was reviewed and approved by the Jiaxing Hospital of Traditional Chinese Medicine Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There is no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Neng-Hua Zhang, Doctor, Associate Chief Physician, Laboratory Department, Jiaxing Hospital of Traditional Chinese Medicine, No. 1501 Zhongshan East Road, Jiaxing 314001, Zhejiang Province, China. znhshzyxwx@163.com
Received: March 28, 2023 Peer-review started: March 28, 2023 First decision: April 11, 2023 Revised: April 21, 2023 Accepted: May 12, 2023 Article in press: May 12, 2023 Published online: June 16, 2023 Processing time: 75 Days and 22.4 Hours
Abstract
BACKGROUND
Pseudomonas aeruginosa (P. aeruginosa) is an important cause of nosocomial infections, and contributes to high morbidity and mortality, especially in intensive care units. P. aeruginosa is considered a 'critical' category bacterial pathogen by the World Health Organization to encourage an urgent need for research and development of new antibiotics against its infections.
AIM
To investigate the effectiveness of baicalin combined with tobramycin therapy as a potential treatment method for carbapenem-resistant P. aeruginosa (CRPA) infections.
METHODS
Polymerase chain reaction (PCR) and RT-PCR were used to detect the expression levels of drug-resistant genes (including VIM, IMP and OprD2) and biofilm-related genes (including algD, pslA and lasR) in CRPA that confer resistance to tobramycin, baicalin and tobramycin combined with baicalin (0, 1/8, 1/4, 1/2 and 1MIC).
RESULTS
There was a correlation between biofilm formation and the expression of biofilm-related genes. In addition, VIM, IMP, OprD2, algD, pslA and lasR that confer biofilm production under different concentrations in CRPA were significantly correlated. The synergistic effect of baicalin combined with tobramycin was a significant down-regulation of VIM, IMP, algD, pslA and lasR.
CONCLUSION
Baicalin combined with tobramycin therapy can be an effective treatment method for patients with CRPA infection.
Core Tip: Baicalin combined with tobramycin therapy shows potential as an effective treatment method for patients with carbapenem-resistant Pseudomonas aeruginosa infection, as it significantly down-regulates drug-resistant and biofilm-related genes.
